Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.320
+0.050 (3.94%)
At close: Jan 21, 2025, 4:00 PM
1.330
+0.010 (0.76%)
After-hours: Jan 21, 2025, 6:20 PM EST
Fate Therapeutics Revenue
Fate Therapeutics had revenue of $3.07M in the quarter ending September 30, 2024, with 58.13% growth. This brings the company's revenue in the last twelve months to $13.45M, down -87.34% year-over-year. In the year 2023, Fate Therapeutics had annual revenue of $63.53M, down -34.03%.
Revenue (ttm)
$13.45M
Revenue Growth
-87.34%
P/S Ratio
10.28
Revenue / Employee
$74,293
Employees
181
Market Cap
150.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 63.53M | -32.77M | -34.03% |
Dec 31, 2022 | 96.30M | 40.45M | 72.44% |
Dec 31, 2021 | 55.85M | 24.41M | 77.66% |
Dec 31, 2020 | 31.43M | 20.75M | 194.33% |
Dec 31, 2019 | 10.68M | 5.94M | 125.32% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
FATE News
- 18 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at Upcoming December Investor Conferences - GlobeNewsWire
- 2 months ago - Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha
- 2 months ago - Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewsWire
- 2 months ago - Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewsWire